Teva Pharma (TEVA) volatility increases on Mylan (MYL) granted FDA approval of Copaxone

Teva Pharma (NYSE: TEVA) October weekly call option implied volatility is at 70 from 40, October is at 56 from 41, November is at 57; compared to its 52-week range of 24 to 61 on Mylan (Nasdaq; MYL) was granted FDA approval of the first generic for Copaxone.

You May Also Be Interested In

• Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
• Western Digital (WDC) call put ratio 1.4 calls to 1 puts
• HealthStream (HSTM) 2300 contracts of July 30 calls trade